drugset
drugset / Trial / NCT04652479

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

NCT04652479 ↗

Phase 2 Completed 25 enrolled Dr. Tracey McLaughlin, MD Eiger BioPharmaceuticals · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.

Timeline

Start
2021-06-21
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Avexitide Peptide 45 mg —
Subject Avexitide Peptide 90 mg —

Indications

hyperinsulinemic hypoglycemia